Du Pont Merck Pharmaceuticalhas signed an agreement with Johnson & Johnson subsidiaryOrtho Pharmaceutical that gives Du Pont exclusive rights outsidethe Pacific Rim to Ortho's Macroscint agent for infection imaging.The agent is a human immunoglobulin
Du Pont Merck Pharmaceuticalhas signed an agreement with Johnson & Johnson subsidiaryOrtho Pharmaceutical that gives Du Pont exclusive rights outsidethe Pacific Rim to Ortho's Macroscint agent for infection imaging.The agent is a human immunoglobulin protein that is labeled withindium-111.
Du Pont of North Billerica, MA, claims that Macroscint is uniquein that it allows nuclear medicine physicians to conduct infectionimaging without the hazards and inconvenience associated withhandling blood from patients. Currently, infection imaging isconducted by drawing a patient's blood, labeling the white bloodcells with a radiotracer and injecting it back into the patient.With Macroscint, physicians inject the radiotracer into the patientlike any other radiopharmaceutical, according to Alan Carpenter,Du Pont's director of business development and planning.
Macroscint has completed phase-three clinical trials and DuPont is preparing a product license application (PLA) to the Foodand Drug Administration.
Du Pont will pay a licensing fee to Ortho for sales of Macroscintas part of the deal. In addition, Du Pont will acquire exclusiverights relating to basic research technology involving infectionimaging and technetium chemistry, according to Carpenter.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.